English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/57002
Title: Optimization of Taxane Binding to Microtubules: Binding Affinity Dissection and Incremental Construction of a High-Affinity Analog of Paclitaxel
Authors: Matesanz, Ruth; Barasoain, Isabel; Yang, C.G.; Wan, L.; Li, X.; Inés, C. de; Coderch, Claire; Gago, Federico; Jiménez-Barbero, Jesús; Andreu Morales, José Manuel; Fang, Wei-shuo S.; Díaz, José Fernando
Keywords: Chembio
Issue Date: 23-Jun-2008
Publisher: Elsevier
Citation: Chemistry and Biology, 15 (6) : 573-585 (2008)
Abstract: The microtubule binding affinities of a series of synthetic taxanes have been measured with the aims of dissecting individual group contributions and obtaining a rationale for the design of novel compounds with the ability to overcome drug resistance. As previously observed for epothilones, the positive and negative contributions of the different substituents to the binding free energies are cumulative. By combining the most favorable substitutions we increased the binding affinity of paclitaxel 500-fold. Insight into the structural basis for this improvement was gained with molecular modeling and NMR data obtained for microtubule-bound docetaxel. Taxanes with affinities for microtubules well above their affinities for P-glycoprotein are shown not to be affected by multidrug resistance. This finding strongly indicates that optimization of the ligand-target interaction is a good strategy to overcome multidrug resistance mediated by efflux pumps
Description: 13 páginas, 5 figuras, 2 tablas -- PAGS nro.s 573-585
Publisher version (URL): http://dx.doi.org/10.1016/j.chembiol.2008.05.008
URI: http://hdl.handle.net/10261/57002
ISSN: 1074-5521
DOI: 10.1016/j.chembiol.2008.05.008
E-ISSN: 1879-1301
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Matesanz et al-2008_Chemistry and Biology.pdf616,68 kBAdobe PDFThumbnail
Show full item record

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.